Nav: Home

MorNuCo Inc. becomes first recipient of award for research and science innovation

June 09, 2016

Dallas, Texas - June 9th, 2016 - MorNuCo Laboratories of West Lafayette, Indiana and its founders, D. James Morré, PhD, and Dorothy M. Morré, PhD, recently received the first ever L. Stephen Coles, MD, PhD Award for Research and Science Innovation in Aging and Age Management Medicine at the AMMG Conference in Orlando Florida on May 14th. This award honors the excellence and significant contributions that MorNuCo Laboratories has worked to achieve since the beginning of their research , including ENOX2 and the ONCOblot® Test. MorNuCo is elated to share this award with the public as they continue to move forward in the fight against cancer.

The award's origin spurs from Dr. Stephen L. Coles, who was a remarkable physician and researcher, who dedicated much of his life to advancing the field of age management. Sadly, the scientific and medical communities lost Dr. Coles in November of 2014. In large part, this award pays homage to Dr. Coles as a shining example of an individual with a desire to drive scientific discovery.

Upon receiving this award, Dr. D. James Morré stated, "It is a true privilege to be recognized for this award given that it is named after such an impactful person to this field."

Undoubtedly the Morrés exemplify the spirit for which this honor is awarded; a passion for discovery and the highest ethics and scientific values in conducting research and innovation within the fields of aging and age management medicine.

With the advent of technologies like the ONCOblot® Test that the Morrés have dedicated their lives to developing, physicians are increasingly finding themselves better prepared to handle age related diseases, such as cancer.

The L. Stephen Coles, MD, PhD Award for Research and Science Innovation in Aging and Age Management Medicine serves as a reminder of how much effort is being put forth to eliminate age related diseases - including cancer. It is a hopeful milestone for a cancer-free future and a wonderful award to solidify decades of hard work by the Morrés.
-end-
About ONCOblot®

The ONCOblot® Test was developed and created by Dr. D. James Morré and Dr. Dorothy M. Morré of MorNuCo, Purdue Research Park, West Lafayette, IN. The Morrés are committed to the premise that understanding cancer is the key to its conquest. The ONCOblot® test is based on more than 20 years of basic research and confirms the presence of cancer and the tissue of origin through the detection of ENOX2.

If you'd like more information about the ONCOblot® Test, please visit http://www.oncoblotlabs.com or e-mail info@oncoblotlabs.com

ONCOblot Labs

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.